Stockscreener 앱 받기
8.14
5.58%
0.43
시간 외 거래:
8.03
-0.11
-1.35%
Seres Therapeutics Inc 주식(MCRB)의 최신 뉴스
Seres Therapeutics outlines its microbiome drug strategy as MCRB works to regain traction - AD HOC NEWS
Price to book forward of Seres Therapeutics, Inc. – NASDAQ:MCRB - TradingView
MCRB News | SERES THERAPEUTICS INC (NASDAQ:MCRB) - ChartMill
Seres Therapeutics (NASDAQ: MCRB) director receives 7,508-share stock option grant - Stock Titan
Form 4 Seres Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada
Seres Therapeutics (NASDAQ: MCRB) director awarded 7,508 stock options at $7.94 - Stock Titan
Seres Therapeutics (MCRB) director awarded 7,508 stock options vesting by 2027 - Stock Titan
Price to sales forward of Seres Therapeutics, Inc. – NASDAQ:MCRB - TradingView
Price to earnings forward of Seres Therapeutics, Inc. – NASDAQ:MCRB - TradingView
Seres Therapeutics to Host Webcast on July 8, 2026, to - GlobeNewswire
This Insulet Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
This Insulet analyst begins coverage on a bullish note; here are top 5 initiations for Tuesday - MSN
H.C. Wainwright Initiates Seres Therapeutics(MCRB.US) With Buy Rating, Announces Target Price $12 - Moomoo
MCRB Initiates Coverage by HC Wainwright & Co. -- Rating Set to Buy - GuruFocus
H.C. Wainwright initiates Seres Therapeutics stock coverage with buy rating - Investing.com
H.C. Wainwright initiates Seres Therapeutics stock coverage with buy rating By Investing.com - Investing.com Nigeria
HC Wainwright Initiates Seres Therapeutics at Buy With $12 Price Target - Moomoo
Seres Therapeutics Inc Cash Flow – DUS:1S90 - TradingView
EBITDA per share of Seres Therapeutics Inc – DUS:1S90 - TradingView
Return on assets % of Seres Therapeutics Inc – DUS:1S90 - TradingView
Total common shares outstanding of Seres Therapeutics Inc – DUS:1S90 - TradingView
Seres Therapeutics Inc (MCRB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Seres Therapeutics Inc (MCRB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Seres Therapeutics Inc (MCRB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Seres Therapeutics Inc (MCRB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Seres Therapeutics Inc (MCRB) Institutional Confidence - TradingKey
Seres Therapeutics Inc (MCRB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Seres Therapeutics Inc (MCRB) Valuation: PE, PB & Fair Value Analysis - TradingKey
Seres Therapeutics Inc (MCRB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Seres Therapeutics Inc (MCRB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Microbiome Therapeutics Market Size, Share | Forecast [2034] - Fortune Business Insights
MCRB Q1 2026 Earnings: EPS Miss as Seres Therapeutics Reports Wider-than-Expected LossDividend Cut Risk - dars.gov.et
Seres Therapeutics (MCRB) Faces Sharp Decline, Tests Key Support LevelsETH Profile - newsline.com
We're A Little Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Rate - Yahoo Finance
Seres Therapeutics (MCRB) Slips 2.62% as Shares Test Key Support at $6.00Bull Pennant - newsline.com
Cambridge biotech surrenders half its lab space amid cash crunch - The Business Journals
MCRB Stock Declines As Seres Therapeutics Pauses SER-155 Phase 2 Study And Shrinks Headcount By 30% - Stocktwits
Seres Therapeutics (MCRB) Secures Cash Runway Extension Through Key Transactions - GuruFocus
Seres Therapeutics Secures $25M from Nestlé, Restructures Lease to Extend Cash Runway Into 2027 - Minichart
Seres Therapeutics secures $25M from Nestlé Health Science By Investing.com - Investing.com South Africa
Seres Therapeutics Reshapes Finances with Lease Restructuring - TipRanks
Seres Therapeutics Extends Cash Runway to 2027 Through Financial Restructuring and Lease Adjustments - geneonline.com
Seres Therapeutics Secures $25 Million from Nestlé Health Science and Reduces Facility Costs to Enhance Financial Position - Quiver Quantitative
Seres Therapeutics Announces Two Transactions To Strengthen Balance Sheet, Reduce On-Going Lease Costs And Extend Projected Operating Cash Runway Well Into The First Quarter Of 2027 - TradingView
Seres Therapeutics secures $25M from Nestlé Health Science - Investing.com
Seres Therapeutics (Nasdaq: MCRB) extends cash runway into 2027 - Stock Titan
Seres Therapeutics Announces Two Transactions to Strengthen - GlobeNewswire
Seres Therapeutics, Inc. Files 8-K Current Report with SEC Detailing Corporate Information (May 30, 2026) - Minichart
[8-K] Seres Therapeutics, Inc. Reports Material Event - Stock Titan
Seres Therapeutics (MCRB) Slips 3.4%, Testing Key Support at $6.95Range Breakout - newsline.com
Seres Therapeutics (MCRB) Declines 2.18% as Stock Approaches Key SupportHigh Reward Trades - newsline.com
Seres Therapeutics (MCRB) Edges Higher Amid Steady Support and Resistance DynamicsDark Pool Volume - The Legal Advocate
MCRBSeres Therapeutics Inc Stock Price and Quote - Finviz
Seres Therapeutics (MCRB) Declines 5.93% as Selling Pressure IntensifiesLow Risk Entry Stocks - The Legal Advocate
MCRB Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Continues R&D FocusEarnings Beat Streak - The Legal Advocate
1.18%
2.48%
자본화:
|
볼륨(24시간):